Introduction
Exposure to occupational and environmental agents can cause a spectrum of airway and interstitial lung diseases that likely involve immune mechanisms, such as occupational asthma, hypersensitivity pneumonitis and chronic granulomatous lung diseases. With generally reduced occupational exposures to the traditional inorganic dusts such as asbestos, silica and coal dust, and the expanding use of new metal and chemical-based products, predominantly immune-mediated lung diseases have become the major reported occupational lung diseases in most developed countries. Isocyanate asthma and chronic beryllium disease, two of the more commonly diagnosed occupational lung diseases, share several features that have hampered recognition and prevention. Only a fraction of exposed workers develop disease, and exposure-response relationships remain poorly defined; both diseases can occur at very low levels of exposure, below current regulatory limits [1 ,2,3 ] . It has been presumed that the respiratory tract is the key route of exposure and site for initiation of the immune responses, with research, regulation and prevention to-date focused almost exclusively on airborne exposures. Despite reductions in workplace respiratory exposures, however, isocyanate asthma and chronic beryllium disease continue to occur, prompting a focus on skin as a route of exposure [1 ,3
This review will highlight recent findings from a diverse literature that, taken together, support the hypothesis that skin may be an important site of exposure and initial sensitization for certain occupational and environmental agents.
Challenges to investigating skin exposures
Exposure to isocyanates and to beryllium, rather than occurring as single agents at constant levels, typically occur as mixed or variable exposures, complicating exposure assessment. Use of both continues to rise, with novel applications and processes creating new opportunities for exposure. Isocyanates, a diverse group of reactive chemicals with the functional group NCO, are used extensively to produce a wide array of polyurethane coatings, foams and others products. The major commercial isocyanates are methylene diphenyl diisocyanate (MDI), toluene diisocyanate (TDI) and hexamethylene diisocyanate (HDI) and numerous polymeric forms and prepolymers Opportunities for isocyanate and beryllium skin exposure can occur in many work settings, including direct contact of unprotected skin with contaminated equipment or surfaces, deposition of airborne exposures, or failure of skin protective equipment. Opportunities for skin exposure may persist after airborne exposure is gone, for example from residual dust particles (beryllium) or polyurethane that is not fully cured and contains residual free NCO [6 ,7 ] . Current beryllium and isocyanate workplace exposures tend to be low, below irritating thresholds, thus workers have few 'warning signs', and may lack adequate skin protective clothing such as gloves. Exposure levels that are low, but sufficient to induce sensitization or elicit responses upon subsequent challenge, can be technically challenging to quantify, and may require highly sensitive methodologies [5, 8] .
Skin exposure assessment methodology is not nearly as well developed as for inhalational exposures, and is further complicated by factors such as the frequently variable and sporadic nature of skin exposure, and uncertain ties regarding skin uptake, and recovery from sampled skin or wipes, and effectiveness of protective clothing. With very limited exposure data available and few dermal exposure models, skin exposure has rarely been incorporated into epidemiologic studies to assess its potential contribution to the risk of lung disease [9, 10] . Thus to-date support for the hypothesis that human skin exposures play a role in the development of systemic sensitization and subsequent lung disease is largely indirect.
Animal studies using skin sensitization
Several different animal models have used isocyanate skin exposure to induce systemic Th2-like sensitization that, when followed by inhalation challenge, induces asthmalike responses in the lung [11] [12] [13] . Murine studies have demonstrated that dose, route and timing of isocyanate exposure are key determinants of sensitization and asthma. In general, relatively modest skin exposure doses (frequency and concentration) are highly effective at inducing Th2-like sensitization, and lower skin doses may paradoxically result in greater lung inflammation following airway challenge [11, 14] . Transgenic mouse models have demonstrated that isocyanates can induce mixed Th1/Th2 responses, and that the immune response is also dependent on the mouse strain [13, 15] .
Unlike isocyanate asthma, chronic beryllium disease has been difficult to replicate in animal models, the great majority of which have used inhalation exposures and lead to acute changes, but not the chronic granulomatous disease. Beryllium sensitization (but not lung disease) has been produced in mice following skin exposure to beryllium oxide particles [16] .
Isocyanate asthma and skin exposure
Isocyanate asthma remains one of the most common causes of occupational asthma worldwide [1 ] . The clinical and pathophysiological presentation of isocyanate asthma is similar to environmental atopic asthma, including Th2-like airway inflammation and hyperreactivity [17] . Isocyanate asthma is reported typically in end-use settings such as spray, foam and adhesive applications, where there can be numerous opportunities for skin exposure [1 ,18 ] . Concern that skin exposure may increase risk for isocyanate sensitization and asthma stems in large part from case reports and limited crosssectional studies reporting isocyanate asthma in settings with opportunities for skin exposure (sometimes accidental exposures) and minimal airborne levels [19, 20] , and also the animal literature [1 ].
Methodologies to assess skin exposure to isocyanates have been particularly challenging due to several factors, including isocyanate chemical reactivity and numerous different isocyanate formulations. Since all sampling methods depend on the presence of free unreacted NCO, the timing of sampling is also critical. Isocyanate skin exposure has recently been documented using newly developed qualitative and quantitative methodologies in auto body shop workers and painters that apply polyurethane products, despite the use of standard personal protective equipment such as gloves, and also in settings where airborne exposures are minimal [18 ,21 ,22 ]. An on-going epidemiological study of auto body shop workers has demonstrated HDI-specific IgG antibodies in over 20% of the workers, which was strongly associated with inhalation exposure, but skin exposure also contributed independently [23] . Together these recent human and animal studies confirm isocyanate skin exposure in the workplace and support the concept that such exposure may lead to sensitization and the subsequent development of isocyanate asthma upon airway challenge.
Chronic beryllium disease and skin exposure
Exposure to beryllium particles (metal, oxides, alloys) can lead to Th1-type sensitization and chronic beryllium disease, an immune-mediated systemic granulomatous disease involving predominantly the lungs, and mediated by CD4þ Th1 responses to beryllium. Similar to isocyanate asthma, new cases of beryllium sensitization (detected by proliferation of beryllium-specific CD4þ T cells), and chronic beryllium disease have occurred despite large reductions in respiratory exposures, including below current regulatory standards (2 mg/m 3 in the United States) [3 ,7 ] . Historically, allergic contact dermatitis and acute pneumonitis were seen following skin and respiratory exposure to soluble beryllium salts (now uncommon). Beryllium sensitization and chronic beryllium disease is seen following inhalation to less soluble beryllium particles [3 ] .
It has been hypothesized that, in addition to respiratory exposure, skin exposure to beryllium particles may induce sensitization, which can progress to chronic beryllium disease following inhalation exposure [4 ,16] . Limited studies suggest that beryllium particles may be able to penetrate human skin [16] , and increased risk of chronic beryllium disease has been reported in workers with skin lesions, possibly related to increased exposure and uptake of beryllium [24] . Additional indirect data suggesting that skin exposure may contribute to beryllium sensitization come from a recent study in a beryllium ceramics facility that implemented an enhanced preventive program that targeted air and skin exposure. Beryllium sensitization was reduced in new workers hired after implementation of the program (1%), compared with workers hired previously (8.7%), during which time airborne beryllium levels, already low, and respirator use, changed little [25 ] . The authors suggested that reduced skin exposure may have contributed to reduced risk of sensitization [25 ] , but skin exposure was not evaluated. Documentation of beryllium skin exposure in workers has been limited, despite awareness that it likely is common, similar to isocyanates. Frequent beryllium contamination of work surfaces and skin exposure was recently documented at a copper-beryllium alloy facility, despite extensive control measures, using beryllium analysis of skin wipes and gloves [7 ] . Incorporation of beryllium and isocyanate skin exposure into epidemiologic studies is needed to address skin exposure-disease relationships.
Loss of skin barrier and development of allergy and asthma
Recent studies in the dermatology, allergy and immunology literature also support the hypothesis that skin exposure to occupational and environmental agents may contribute to the development of lung disease. The skin is an active immunologic organ. Repeated skin exposure to numerous substances, primarily metals and certain chemicals are well known to induce contact dermatitis, a delayed-type hypersensitivity reaction in the skin, typically mediated by Th1 CD4þ and CD8þ T cells. Much less is known about skin immune responses to substances that typically induce primarily Th2 sensitization and lung rather than skin disease, such as protein allergens or asthmagenic chemicals.
Several recent studies have suggested that skin exposure to environmental allergens, facilitated by impaired skin barrier function, may promote the development of atopy, atopic dermatitis and eventually atopic asthma, supporting the 'atopic march' hypothesis [26, 27] . Mutations in the gene encoding filaggrin, a protein that helps maintain the epithelial barrier, have been shown to impair epithelial barrier function [27] . Several recent genetic studies have found that these filaggrin mutations are associated with an increase risk for atopy, atopic dermatitis and asthma [26, 28 ]. The highest risk of asthma was in those with atopic dermatitis [28 ] , supporting the concept that environmental allergens can cross the epidermis barrier and induce Th2-like sensitisation [29] . These findings are consistent with murine models of atopic asthma in which epicutaneous allergen exposure is highly effective at inducing Th2-like sensitization and subsequent lung asthmatic responses following airway challenge [30] .
Limited studies on food allergens have also recently focused on the role of skin exposure. Epicutaneous exposure to peanut protein in mice can induce potent Th2-type immune responses and prevent the normal induction of oral tolerance to peanuts [31] . Peanut allergy was associated with the use of skin creams containing peanut oil in an epidemiological study of preschool children [32] .
Together these diverse studies support the hypothesis that skin may be an important site for systemic sensitization to certain environmental agents, and that factors that disrupt epidermal barrier function may increase skin exposure, promoting sensitization, asthma and food allergies [33 ] . Similarly, in the workplace, host factors such as eczema, as well as co-exposures (e.g. solvents, other chemicals, trauma, hand washing) may enhance trans-epidermal skin uptake of allergens such as isocyanates or beryllium, leading to sensitization and the subsequent development of lung disease following inhalation exposure [29, 34] .
Conclusion
Recent developments collectively support a greater focus on the role of skin exposure in promoting sensitization and the development of asthma and other primarily immune-mediated lung diseases caused by occupational and environmental exposures. If such exposures contribute to disease, workplace exposure monitoring practices that focus exclusively on airborne exposures may falsely indicate 'safe' exposure levels, and may lead to misdiagnosis or ongoing exposure to the causative agent. Further research is needed to define risks of skin exposure and dose-response relationships, define mechanistic pathways, and develop more effective strategies for prevention. There are sufficient data, however, to conclude that it is prudent to attempt to minimize both skin and inhalation workplace exposures.
